People with the rare disease Lambert-Eaton Myasthenic Syndrome (LEMS) have had almost no treatment options for over 35 years. That has meant a lot of suffering for LEMS patients who deal with muscle weakness and fatigue daily. But now there is new hope, thanks to the work of Catalyst Pharmaceuticals.

Catalyst is a Florida company focused on helping rare disease patients who don't have many good treatment options. In 2018, Catalyst achieved something huge. They got the first LEMS treatment approved by the FDA in over three decades!

This breakthrough drug is called Firdapse. It can help LEMS patients improve their muscle strength and gain back independence in their daily lives. Getting Firdapse approved was really hard. Catalyst had to run big clinical trials to prove it really worked for LEMS. But their determination paid off, and now LEMS patients’ lives are being changed.

Helping rare disease patients is personal for the team at Catalyst. Their shared values of passion, trust and integrity drive everything they do - from the science to how they run the business. Catalyst also works very closely with LEMS patient communities. They get real-world advice from patients to make sure they stay focused on what matters most - making lives better.

But Catalyst isn't stopping now. They are still growing globally while looking into new treatments for rare diseases without good options today. Catalyst is also making Firdapse more affordable and accessible for all LEMS patients who need it.

For LEMS patients, Catalyst has shown the power of not giving up hope, even after 35 quiet years. Now patients have a true champion in their corner. Catalyst's work aims to inspire similar breakthrough solutions for other overlooked illnesses in the future.